Pair Name	alpha-Mangostin, Sorafenib
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Expression	LRRC8A	hsa56262
	Down-regulation	Phosphorylation	MAPK1	hsa5594
	Down-regulation	Phosphorylation	MTOR	hsa2475
	Up-regulation	Expression	PRKAA1	hsa5562
	Up-regulation	Expression	RNF181	hsa51255
In Vivo Model	Hep3B and MHCC97L cells (5×10⁶) were injected subcutaneously into the right flank of the male BALB/c nude mice (4–6 weeks old).
Result	Our results highlight the synergistic effect of the combination of sorafenib and α-Mangostin, which indicates a potential treatment for advanced HCC for patients that are not sensitive to sorafenib therapy.

Pair Name	alpha-Mangostin, Sorafenib
Disease Info	[ICD-11: 2C30]	Melanoma		Investigative
Biological Phenomena	Induction-->Endoplasmic reticulum stress
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Down-regulation	Expression	ATG5	hsa9474
	Up-regulation	Phosphorylation	EIF2S1	hsa1965
	Down-regulation	Expression	MAP1LC3A	hsa84557
	Up-regulation	Expression	MAP1LC3B	hsa81631
	Down-regulation	Phosphorylation	MAPK1	hsa5594
	Down-regulation	Expression	MCL1	hsa4170
	Down-regulation	Expression	MITF	hsa4286
In Vitro Model	SK-MEL-2	Melanoma	Homo sapiens (Human)	CVCL_0069
	SK-MEL-30	Cutaneous melanoma	Homo sapiens (Human)	CVCL_0039
Result	These data demonstrate an unanticipated synergy between α-Mangostin and sorafenib, with mechanistic actions that convert a known safe natural product to a candidate combinatorial therapeutic agent.